期刊文献+

MR多参数联合评估局部进展期乳腺癌新辅助化疗疗效的应用价值 被引量:14

The Application Value of MR Multi-Parameter Combination Evaluation of the Curative Effect of Neoadjuvant Chemotherapy for Local Advanced Breast Cancer
原文传递
导出
摘要 目的探讨MRI多参数联合评价局部进展期乳腺癌新辅助化疗(NAC)疗效的效能。方法回顾性分析127例经术前穿刺、术后病理确诊的局部进展期乳腺癌。分别于NAC前、NAC 2周期后、4周期后行动态MRI增强扫描及DWI成像。按照Miller&Payne改良病理反应性分级,将所有病例分为组织学反应显著(MHR)与组织学非显著反应组(NMHR)。以病理反应性为应变量,分别对NAC 2、4周期后获得的MRI半定量参数进行分析。建立Logistic回归模型并构建新的参数,研究各新构建参数评价乳腺癌NAC反应性的效能。结果 NAC 2周期后新构建参数ROC曲线下面积(Az)为0.80(95%CI:0.72-0.87),大于单独使用癌灶最大径变化率作为评价指标(Az=0.66,95%CI:0.57-0.76)(P〈0.05),最佳截断点1.81,敏感性及特异性分别为76.81%和72.41%;NAC 4周期后,新构建参数ROC曲线下面积(Az)为0.86(95%CI:0.79-0.93),大于单独使用第4周期后癌灶最小ADC(Az=0.75,95%CI:0.67-0.84)及癌灶最大径变化率(Az=0.73,95%CI:0.62-0.80)(P〈0.05)作为评价指标,最佳截断点-1.19,敏感性及特异性分别为84.06%和81.03%。结论 MRI多参数联合评价局部进展期乳腺癌NAC疗效具有较高诊断效能,能充分利用各指标信息。 Objective To discuss the clinical value of MR multi-parameter combination evaluation of the curative effect of neoadjuvant chemotherapy( NAC) for local advanced breast cancer Methods A total of 127 females patients with pathologically-proved local advanced breast cancer were enrolled in this study. Dynamic enhanced MRI and diffusion weighted imaging( DWI) were performed before NAC as well as after 2 and 4 cycles of NAC in all patients. According to Miller Payne modified pathologic reaction grading,the patients were divided into major histological response group( MHR) and non-major histological response group( NMHR). Taking the pathological response as the dependent variable,the semiquantitative MRI parameters obtained after 2 and 4 cycles of NAC were analyzed. The step-wise logistic regression model was established and the new parameters were constructed,and the value of the newly-constructed parameters in assessing the pathologic response to NAC was analyzed. Results After the second cycle of NAC,the area under curve( Az) of the new parameter was 0. 80( 95% CI: 0. 72- 0. 87),which was significantly higher than that obtained by using the variance rate of the maximum diameter alone( Az = 0. 66,95% CI: 0. 57- 0. 76). The optimal diagnostic cut-off point was 1. 81,and the diagnostic sensitivity and specificity were 76. 81% and 72. 41% respectively. After 4 cycle S of NAC,the area under curve( Az) of the new parameter was 0. 86( 95% CI: 0. 79- 0. 93),which was significantly higher than that obtained by using the minimum ADC of tumor( Az = 0. 75,95% CI: 0. 67- 0. 84) or by using the variance rate of the maximum diameter alone( Az = 0. 73,95% CI: 0. 62- 0. 80)( P〈0. 05). The optimal diagnostic cut-off point was- 1. 19,and the diagnostic sensitivity and specificity were 84. 06% and 81. 03% respectively. Conclusion MRI multi-parameter combination evaluation of the curative effect of neoadjuvant chemotherapy for local advanced breast cancer is highly effective,and this method can make full use of MRI information.
出处 《临床放射学杂志》 CSCD 北大核心 2015年第4期539-543,共5页 Journal of Clinical Radiology
基金 医学物理和工程北京市重点实验室开放课题:乳腺MR诊断(编号:2008P03)
关键词 乳腺癌 磁共振成像 新辅助化疗 病理学 联合 Breast cancer Magnetic resonance imaging Neoadjuvant chemotherapy Pathology Combination
  • 相关文献

参考文献15

  • 1Reiko Woodhams, Satoko Kakita, Hirofumi Hata, et al. Identification of Residual Breast Carcinoma Following Neoadjuvant Chemotherapy: Diffusion-weighted Imaging-Comparison with Contrast-enhanced MR Imaging and Pathologic Findings [ J ]. Radiology, 2010, 254 : 357- 366.
  • 2Meisamy S, Bolan PJ, Baker EH, et al. Neoadjuvant Chemotherapy of Locally Advanced Breast Cancer: Predicting Response with in Vi- vo ~I MR Spectroscopy-A Pilot Study at 4 T [ J ]. Radiology,2004,233:424-431.
  • 3Ah-See ML, Makris A, Taylor N J, et al. Early changes in functional dynamic magnetic resonance imaging predict for pathologic response to neoadjuvant chemotherapy in primary breast cancer [ J ]. Clinical Cancer Research ,2008,14:6580-6589.
  • 4Pickles MD, Manton D J, Lowry M, et al. Prognostic value of pre- treatment DCE-MRI parameters in predicting disease free and overall survival for breast cancer patients undergoing neoadjuvant chemo- therapy[ J]. European Journal of Radiology,2009,71:498-505.
  • 5Ltidemann L, Wust P, Gellermann J. Perfusion measurement using DCE-MRI : implications for hyperthermia [ J ]. Int J Hyperthermia, 2008,24:91-6.
  • 6武春雪,王霄英,秦乃姗,郭丽,蒋学祥.MR测量癌灶大小对局部进展期乳腺癌新辅助化疗的疗效评估[J].实用放射学杂志,2010,26(1):77-83. 被引量:8
  • 7Ogston KN, Miller ID, Payne S, et al. A new histological grading sys- tem to assess response of breast cancers to primary chemotherapy: prognostic significance and survival [ J ]. Breast, 2003,12 : 320-327.
  • 8Kuhl CK,Mielcareck P, Klaschik S, et al. Dynamic breast MR ima- ging : are signal intensity time course data useful for differential diag- nosis of enhancing lesions? [ J~. Radiology, 1999,211 : 101-110.
  • 9Buadu LD, Murakami J, Murayama S, et al. Breast lesions : correla- tion of contrast medium enhancement patterns on MR images with histopathologic findings and tumor angiogenesis [ J ]. Radiology, 1Qc~6 200.6qq-A.q.
  • 10石桥,王霄英,郭丽,秦乃姗,蒋学祥.MRI动态增强流出参数半定量分析对局部进展期乳腺癌新辅助化疗疗效评估的价值[J].中华放射学杂志,2013,47(8):699-703. 被引量:10

二级参考文献40

  • 1Fitzek C,Mentzel HJ,Fitzek S,Sauner D,Kaiser WA,Reichenbach JR.Echoplanar diffusion - weighted MRI with intravenous gadolinium - DTPA[J].中国神经肿瘤杂志,2003,1(4):235-235. 被引量:15
  • 2刘溢,谢敬霞,韩鸿宾,杨渝平,刘淳.磁共振扩散加权成像在乳腺肿瘤的初步应用[J].中国医学影像技术,2003,19(5):548-551. 被引量:38
  • 3Lee KC, Moffat BA, Schott AF, et al. Prospective early re- sponse imaging biomarker for neoadjuvant breast cancer chemo- therapy. Clin Cancer Res, 2007,13(2 Pt 1):443-450.
  • 4Woodhams R, Kakita S, Hata H, et al. Identification of residual breast carcinoma following neoadjuvant chemotherapy: diffusion- weighted imaging-comparison with contrast-enhanced MR imaging and pathologic findings. Radiology, 2010,254(2) :357-366.
  • 5Ogston KN, Miller ID, Payne S, et al. A new histological grad- ing system to assess response of breast cancers to primary chemo- therapy: prognostic significance and survival. Breast, 2003, 12 (5) :320-327.
  • 6Segara D, Krop IE, Garber JE, et al. Does MRI predict patho- logic tumor response in women with breast cancer undergoing pre- operative chemotherapy? J Surg Oncol, 2007,96(6):474-480.
  • 7Ross BD, Moffat BA, Lawrence TS, et al. Evaluation of cancer therapy using diffusion magnetic resonance imaging. Mol Cancer Ther, 2003,2(6) : 581-587.
  • 8Fisher ER, Wang J, Bryant J, et al. Pathobiology of preopera- tive chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) protocol B-18. Cancer, 2002,95(4) : 681-695.
  • 9Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: finding from National Surgical Adjuvant Breast and Bowel Project 13-18. J Clin Oncol, 1997,15(7):2483-2493.
  • 10Sharma U, Danishad KK, Seenu V, et al. Longitudinal study of the assessment by MRI and diffusion-weighted imaging of tumor response in patients with locally advanced breast cancer undergo- ing neoadjuvant chemotherapy. NMR Biomed, 2009,22 (1) : 104- 113.

共引文献97

同被引文献116

引证文献14

二级引证文献109

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部